Home Cart Sign in  
Chemical Structure| 1093070-16-6 Chemical Structure| 1093070-16-6

Structure of GRL0617
CAS No.: 1093070-16-6

Chemical Structure| 1093070-16-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GRL0617 is a noncovalent lead inhibitor of Plpro. It inhibited SARS-CoV viral replication in Vero E6 cells with an EC50 of 15μM。

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GRL0617

CAS No. :1093070-16-6
Formula : C20H20N2O
M.W : 304.39
SMILES Code : O=C(N[C@@H](C1=C2C=CC=CC2=CC=C1)C)C3=CC(N)=CC=C3C
MDL No. :MFCD12547683
InChI Key :UVERBUNNCOKGNZ-CQSZACIVSA-N
Pubchem ID :24941262

Safety of GRL0617

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 4.7 μM Inhibition of Nsp3 deISGylase activity Nat Commun. 2023 Mar 28;14(1):1733
Vero E6 cells 14.5 μM Inhibition of SARS-CoV-2 viral replication Nat Commun. 2023 Mar 28;14(1):1733
CaCo-2 cells 100 μM 48 hours To evaluate the inhibitory effect of GRL-0617 on SARS-CoV-2-induced cytopathogenic effect (CPE), results showed that 100 μM GRL-0617 almost completely inhibited CPE. Nature. 2020 Nov;587(7835):657-662
HeLa cells 100 nM various time points To evaluate the inhibitory effect of GRL-0617 on SCoV2-PLpro, results showed that GRL-0617 effectively blocked SCoV2-PLpro activity, leading to increased levels of ISGylated proteins. Nature. 2020 Nov;587(7835):657-662
Vero E6 cells 100 μM 48 hours To test the antiviral activity of GRL0617 against SARS-CoV-2. Results showed 100 μM GRL0617 inhibited over 50% viral replication with no apparent cytotoxicity. Nat Commun. 2021 Jan 20;12(1):488
HEK293T cells 20-80 μM 24 hours To assess the inhibitory effect of GRL0617 on the deubiquitinating and deISGylating activities of SARS-CoV-2 PLpro. Results showed GRL0617 could partially restore poly-ubiquitin-conjugates and ISG15-conjugates in cells. Nat Commun. 2021 Jan 20;12(1):488
Caco2-hACE2 19.96 μM 24 hours To evaluate the antiviral activity of GRL0617 against SARS-CoV-2. GRL0617 inhibited SARS-CoV-2 with an EC50 of 19.96 μM in Caco2-hACE2 cells. ACS Cent Sci. 2021 Jul 28;7(7):1245-1260
VERO E6 20 μM 24 hours To evaluate the antiviral activity of GRL0617 against SARS-CoV-2. GRL0617 inhibited SARS-CoV-2 with an EC50 of 23.64 μM in Vero E6 cells. ACS Cent Sci. 2021 Jul 28;7(7):1245-1260
Vero E6 cells 10-15 μM 48 hours To evaluate the antiviral activity of GRL0617 against SARS-CoV, showing an EC50 of 15 μM with no cytotoxicity. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.29mL

0.66mL

0.33mL

16.43mL

3.29mL

1.64mL

32.85mL

6.57mL

3.29mL

References

 

Historical Records

Categories